Evidence map›Paper›PMID 40888878›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Imidazopyridine DSH65 induces intrinsic apoptosis and cell cycle arrest in burkitt lymphoma cells.

Lisandra de Oliveira Silva, Laura Otto Walter, Natália Marceli Stefanes, João Vitor Steimbach, Paulo Henrique Schneider, Helena Domingues de Salles, Ricardo Ferreira Alffeldt, Maria Cláudia Santos-Silva

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. (-)-Epi-Osmundalactone-Rich Fraction fromPlants (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lisandra de Oliveira SilvaExperimental Oncology and Hemopathies Laboratory, Clinical Analysis Department, Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0000-0003-2727-1540
Laura Otto WalterExperimental Oncology and Hemopathies Laboratory, Clinical Analysis Department, Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0000-0003-3957-619X
Natália Marceli StefanesExperimental Oncology and Hemopathies Laboratory, Clinical Analysis Department, Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0000-0002-6104-1450
João Vitor SteimbachExperimental Oncology and Hemopathies Laboratory, Clinical Analysis Department, Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0000-0002-7640-2474
Paulo Henrique SchneiderFederal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 91501-970, Brazil.ORCID http://orcid.org/0000-0003-4082-7152
Helena Domingues de SallesFederal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, 91501-970, Brazil.ORCID http://orcid.org/0000-0002-5552-0383
Ricardo Ferreira AlffeldtPost-Graduation On Program in Chemical, Physical and Mathematics Sciences Center, Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88040-900, Brazil.ORCID http://orcid.org/0000-0003-0672-8396
Maria Cláudia Santos-SilvaExperimental Oncology and Hemopathies Laboratory, Clinical Analysis Department, Federal University of Santa Catarina, Florianópolis, Santa Catarina, 88040-900, Brazil. maria.claudia.silva@ufsc.br.ORCID http://orcid.org/0000-0003-3916-6473

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burkitt lymphoma (BL) is a germinal center-derived B-cell neoplasm. Due to the aggressiveness of this neoplasm, treatment must be started quickly. Despite innovation in the pharmaceutical industry, BL has high recurrence and mortality rates. Thus, this study aimed to evaluate the cytotoxic effect of an imidazopyridine (DSH65) on BL lineage cells, and to investigate its main mechanisms of cell death. Initially, the concentration-and-time-response curves were evaluated in Daudi and PBMC cells. DSH65 showed IC

Indexed as

Antineoplastic AgentsApoptosisBurkitt LymphomaCell Cycle CheckpointsPyridinesCell Line, TumorDose-Response Relationship, DrugHumansImidazolesReactive Oxygen SpeciesAntineoplastic AgentsImidazolesimidazopyridinePyridinesReactive Oxygen SpeciesApoptosisBurkitt lymphomaImidazopyridineROS

Identifiers

PMID40888878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.